Compare YSXT & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YSXT | ECOR |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.9M | 39.6M |
| IPO Year | 2024 | 2018 |
| Metric | YSXT | ECOR |
|---|---|---|
| Price | $1.26 | $4.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $25.50 |
| AVG Volume (30 Days) | ★ 1.1M | 41.5K |
| Earning Date | 02-15-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $71,452,736.00 | $29,835,000.00 |
| Revenue This Year | N/A | $28.61 |
| Revenue Next Year | N/A | $41.21 |
| P/E Ratio | $6.96 | ★ N/A |
| Revenue Growth | 22.04 | ★ 27.90 |
| 52 Week Low | $1.13 | $4.16 |
| 52 Week High | $9.96 | $19.49 |
| Indicator | YSXT | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | 32.14 | 41.80 |
| Support Level | $1.21 | $4.41 |
| Resistance Level | $1.34 | $5.00 |
| Average True Range (ATR) | 0.19 | 0.26 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 17.91 | 21.54 |
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services and Software Development and Information Technology Services. Key revenue is generated from Auto Insurance Aftermarket Value-added Services segment which include four types value added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services and vehicle maintenance and other value-added services.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.